Search Drug Information, Interactions, Images, Dosage & Side Effects

Coeliac disease bidirectionally linked to IBD 30 Sep 2022
A two-way association exists between coeliac disease (CeD) diagnosis and inflammatory bowel disease, which demands attention in the initial assessment and follow-up of such conditions, according to a study. Regardless of temporal sequence, this co-occurrence indicates a shared aetiology.

Secondary kidney stones: to remove or not?

30 Sep 2022

Artificial liver device improves outcomes, but with safety concerns

30 Sep 2022

Brolucizumab for neovascular age-related macular degeneration holds up in real world

30 Sep 2022

Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients

30 Sep 2022

Ruxolitinib cream achieves durable itch-free state in atopic dermatitis

29 Sep 2022

SGLT2 inhibitors potentially protective against dry eye disease

29 Sep 2022

Low-, very low-dose bevacizumab for retinopathy of prematurity yield good outcomes

29 Sep 2022

Apixaban better than enoxaparin for extended-duration VTE prophylaxis after surgery

29 Sep 2022

Unilateral radiation leads to fewer contralateral nodal failure in AJCC-7 T1-2N2b tonsillar cancer

29 Sep 2022

Renal denervation bounces back in 3-year follow-up study

29 Sep 2022

Modifying RA disease course with novel DMARDs 21 Sep 2022;
Treatment with disease-modifying antirheumatic drugs (DMARDs) continues to be the centre of expert recommendations for rheumatoid arthritis (RA), with particular focus on treat-to-target rather than agent-specific strategy. In an interview with MIMS Doctor, Dr Ho SO, Specialist in Rheumatology and Assistant Professor at the Chinese University of Hong Kong, provided an overview of current RA management principles and how newer therapies, including targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors, may benefit patients with active RA.

Achieving remission with a bypassing agent and immunosuppression in a young man with atypical presentation of acquired haemophilia A

Dr. Ka-Wai Wong, 21 Sep 2022

Effective anticoagulant reversal in elderly patients requiring neurosurgery due to traumatic brain injuries

Dr. Danny Chan, 21 Sep 2022

Stepped approach to weight reduction in adults with obesity

Dr. Rose Zhao-Wei Ting, 20 Sep 2022

Shingrix

Contents : Herpes zoster vaccine: Varicella zoster virus glycoprotein E antigen (recombinant, adjuvanted)

Indications/Uses : Prevention of herpes zoster & post-herpetic neuralgia in adults ≥50 yr; adults ≥18 yr at increased risk of herpes zoster.

Dupixent

Contents : Dupilumab

Indications/Uses : Treatment of moderate to severe atopic dermatitis in adults & adolescents ≥12 yr who are candidates for systemic therapy; severe atopic dermatitis in childn 6-11 yr who are candidates for systemic therapy. Add-on maintenance treatment for severe asthma w/ type 2 inflammation characterised by raised blood eosinophils &/or raised fraction of exhaled nitric oxide (FeNO) in adults & adolescents ≥12 yr who are inadequately controlled w/ high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment. 300 mg: Add-on therapy w/ intranasal corticosteroids for the treatment of adults w/ severe chronic rhinosinusitis w/ nasal polyposis (CRSwNP) for whom therapy w/ systemic corticosteroids &/or surgery do not provide adequate disease control.

Evenity

Contents : Romosozumab

Indications/Uses : Severe osteoporosis in postmenopausal women at high risk of fracture.

Vocabria

Contents : Cabotegravir

Indications/Uses : Tab In combination w/ rilpivirine tab for the short-term treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen w/o present or past evidence of viral resistance to, & no prior virological failure w/, agents of the NNRTI & integrase inhibitor class as: oral lead-in to assess tolerability prior to administration of long-acting cabotegravir + rilpivirine inj; oral therapy for adults who will miss planned dosing w/ cabotegravir + rilpivirine inj. Susp for inj In combination w/ rilpivirine inj for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen w/o present or past evidence of viral resistance to, & no prior virological failure w/, agents of the NNRTI & integrase inhibitor class.